1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
PHS 2026 Omnibus Solicitation of the NIH for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) is sponsored by National Institutes of Health (NIH). PHS 2026 Omnibus Solicitation of the NIH for Small Business Innovation Research Grant Applications (Parent SBIR R43/R44) is a grant from the National Institutes of Health (NIH) that funds small businesses developing innovative biomedical technologies and health-related products …
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93. 837 -- Cardiovascular Diseases Research 93.
847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research 93. 242 -- Mental Health Research Grants 93. 867 -- Vision Research 93.
838 -- Lung Diseases Research 93. 395 -- Cancer Treatment Research 93. 307 -- Minority Health and Health Disparities Research 93.
273 -- Alcohol Research Programs 93. 865 -- Child Health and Human Development Extramural Research 93. 840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders 93.
394 -- Cancer Detection and Diagnosis Research 93. 839 -- Blood Diseases and Resources Research 93. 233 -- National Center on Sleep Disorders Research 93.
393 -- Cancer Cause and Prevention Research 93. 351 -- Research Infrastructure Programs 93. 350 -- National Center for Advancing Translational Sciences 93.
313 -- NIH Office of Research on Women's Health 93. 855 -- Allergy and Infectious Diseases Research 93. 853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders 93.
859 -- Biomedical Research and Research Training Last Updated: May 13, 2026 View version history on Grants.
gov The National Institutes of Health (NIH), including the following NIH Institutes and Centers (ICs): NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDDK, NIGMS, NIMH, NIMHD, NINDS, NCATS, ORIP, and ORWH, intends to publish a Notice of Funding Opportunity (NOFO) to invite eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough grant applications.
The main objective of a SBIR/STTR Phase II award is to continue R&D efforts to advance a technology toward commercialization. If the technology is not available for sale or use by the end of the SBIR/STTR Phase II award, the SBC must use non-SBIR/STTR funds to reach market access.
This funding gap, between the end of the SBIR/STTR Phase II award and customer access, which affects most medical biotechnology products, is known as the “Valley of Death.
” The NIH Phase IIB Strategic Breakthrough award provides additional support to mitigate this funding gap for projects that require extraordinary time and effort, including those requiring regulatory approval or are developing complex instrumentation, clinical research tools, or behavioral interventions. Applications are not being solicited at this time.
Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the R44 activity code. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this NOFO are encouraged to begin to consider applying for this new NOFO.
In addition, collaborative investigations combining expertise will be encouraged and these investigators should also begin considering applying for this application. Prospective applicants should keep in mind that they must demonstrate not less than 100 percent matching funds to be considered for a Phase IIB Strategic Breakthrough award.
Only United States small business concerns (SBCs) that have previously received an NIH SBIR or STTR Phase II award are eligible to submit applications for this opportunity. Only one NIH Phase IIB Strategic Breakthrough award is allowed per project.
This NOFO supports Renewal/Resubmission "Type 2" Applications from recipients with NIH Phase II SBIR/STTR awards that are submitted within the first six due dates following the expiration of their budget period. Grantor contact information NIH SEED (Small business Education and Entrepreneurial Development) NIH SEED (Small business Education and Entrepreneurial Development) No documents are currently available.
Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Small businesses developing biomedical technologies. Confirm the full requirements in the official notice before applying.
The current listing shows phase I up to $323,090; Phase II up to $2,153,927 (SBA guideline); some NIH ICs allow more. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for PHS 2026 Omnibus Solicitation of the NIH for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) are due January 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
PHS 2026 Omnibus Solicitation of the NIH for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article